Jupiter Topco LLC Buys Shares of 23,254 Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Jupiter Topco initiated a position in Supernus Pharmaceuticals, buying 23,254 shares worth approximately $1.08 million. Several other institutional investors also established new stakes during the second quarter.
• Analyst sentiment is broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $62.83, although individual ratings range from sell to strong buy.
• Supernus reported quarterly revenue of $219.06 million, up 32.4% year over year and above estimates, but posted a loss of $1.01 per share versus expectations for $0.42 in earnings. Shares opened at $43.53, near the company’s 12-month low.

Jupiter Topco LLC bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 23,254 shares of the specialty pharmaceutical company's stock, valued at approximately $1,082,000.

Other hedge funds have also made changes to their positions in the company. Elmind Capital LP bought a new stake in shares of Supernus Pharmaceuticals in the second quarter worth $3,255,700. ADAR1 Capital Management LLC bought a new position in Supernus Pharmaceuticals during the 2nd quarter valued at $1,295,000. Hsbc Holdings PLC bought a new position in Supernus Pharmaceuticals during the 2nd quarter valued at $424,000. PDT Partners LLC acquired a new position in Supernus Pharmaceuticals during the 2nd quarter worth $1,203,000. Finally, Canada Pension Plan Investment Board acquired a new position in Supernus Pharmaceuticals during the 2nd quarter worth $823,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings restated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Wall Street Zen downgraded Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Cantor Fitzgerald boosted their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an "overweight" rating in a report on Thursday, July 9th. Finally, Zacks Research upgraded Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $62.83.

Supernus Pharmaceuticals Trading Down 1.0%

Shares of Supernus Pharmaceuticals stock opened at $43.53 on Friday. Supernus Pharmaceuticals, Inc. has a twelve month low of $42.45 and a twelve month high of $59.68. The stock has a market capitalization of $2.53 billion, a price-to-earnings ratio of -22.67, a PEG ratio of 0.80 and a beta of 0.56. The business's 50 day simple moving average is $46.69 and its 200-day simple moving average is $48.41.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The company had revenue of $219.06 million during the quarter, compared to analyst estimates of $205.31 million. During the same period in the prior year, the business earned $0.40 earnings per share. Supernus Pharmaceuticals's quarterly revenue was up 32.4% on a year-over-year basis. Sell-side analysts predict that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source